NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

You are correct. Thanks for the clarification about the murcidencel Keytruda combo sponsor and supporting collaborators:



NCI and Merck are supporting as a collaborators of the study referenced below:




Murcidencel (DCVax-L) is discussed beginning at minute 40, to focus on Keytruda (pembrolizumab) plus DCVax in combo at UCLA, skip to minute 45:40

Group A (pembrolizumab, ATL-DC, poly ICLC)
Beginning 14 days prior to scheduled surgery, patients receive pembrolizumab IV over 30 minutes. After surgery, patients receive pembrolizumab IV over 30 minutes on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.

Group B (placebo, ATL-DC, poly ICLC)
Beginning 14 days prior to scheduled surgery, patients receive placebo IV. After surgery, patients receive placebo IV on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.





https://connect.uclahealth.org/2021/03/22/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020/

https://clinicaltrials.gov/ct2/show/NCT04201873

https://connect.uclahealth.org/2022/09/14/brain-cancer-discovery-clinical-trials/

For information about an earlier murcidencel study which is completed, visit the link below:

https://academic.oup.com/neuro-oncology/article/24/Supplement_7/vii66/6826190?login=false